Alnylam Pharmaceuticals
Alnylam Pharmaceuticals raises $360M Convertible Note at $25B valuation
Quick Facts
Alnylam Pharmaceuticals: Convertible Note Funding Round
Alnylam Pharmaceuticals has successfully raised $360M in Convertible Note funding, reaching a valuation of $25B.
Company Overview
RNAi therapeutics
Funding Details
The Convertible Note round was led by Millennium Partners, with participation from Polaris Partners, Temasek Holdings.
Company Information
- Headquarters: 675 West Kendall Street, Cambridge, MA 02142
- Founded: 2002
- Employees: 2000+
- Category: Biotech
Investment
Alnylam Pharmaceuticals plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Millennium Partners: Verified investor in Convertible Note
- Polaris Partners: Verified investor in Convertible Note
- Temasek Holdings: Verified investor in Convertible Note
Key Investors
About the Author
Related Company Reports
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...